Indications & formulation #
Schizophrenia in adults; bipolar depression uses a different schedule. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral immediate-release tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Day 1: 25 mg twice daily. Increase cautiously toward 300–400 mg/day by day 4 only if tolerated. Selected schizophrenia range 150–750 mg/day; maximum 750 mg/day.
Contraindications & important cautions #
Review sedation, orthostasis, falls, metabolic effects and QT risk. Dementia-related psychosis carries excess mortality risk.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Sedation, orthostasis and metabolic effects may be clinically important.
Interactions #
CYP3A4 inhibitors/inducers can substantially alter exposure; immediate- and extended-release instructions differ.
Monitoring #
Review daytime function, falls/orthostasis, metabolic status and the exact schizophrenia or bipolar indication.
Special populations #
Hepatic impairment: start 25 mg/day and titrate slowly. Older adults need a slower schedule; strong CYP3A4 inhibitors require substantial reduction.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Gradual withdrawal reduces rebound insomnia/nausea. Re-initiation after a significant interruption requires retitration.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Quetiapine
Acute bipolar depression
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 50 mg at bedtime on day 1.
- Titration
- 100 mg day 2, 200 mg day 3, 300 mg day 4, if tolerated.
- Treatment range / target
- 300 mg at bedtime.
- Maximum / limits
- 300 mg/day for this labeled indication.
- Trial & duration
- Assess depressive symptoms and tolerability; maintenance is a separate phase decision.
- Monitoring
- Sedation, orthostasis, weight and metabolic changes.
- Population & organ-function adjustments
- Hepatic impairment: start 25 mg/day and titrate slowly. Older adults: slower individualized titration.
- Important cautions
- Review strong CYP3A4 interactions and fall risk.
Open the condition treatment guide ↗
Quetiapine
Acute bipolar I mania
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 50 mg twice daily on day 1.
- Titration
- Total daily doses 200, 300 and 400 mg on days 2–4; later increments ≤200 mg/day, up to 800 mg by day 6 if tolerated.
- Treatment range / target
- 400–800 mg/day in divided doses.
- Maximum / limits
- 800 mg/day.
- Trial & duration
- Acute stabilization; reassess continuation after recovery.
- Monitoring
- Orthostasis, sedation and metabolic parameters.
- Population & organ-function adjustments
- Hepatic impairment: 25 mg/day initially, slower increments; older/frail patients require slower titration.
- Important cautions
- Immediate-release schedule; do not apply to extended-release tablets.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Quetiapine — Oral immediate-release tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral immediate-release tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- Quetiapine immediate-release tablets — product label, section 2 · United States · Checked 2026-10-26 · Supports: Quetiapine — Acute bipolar depression (Immediate-release tablets); Quetiapine — Acute bipolar I mania (Immediate-release tablets)